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Abstract (75 word limit) 26 
Vulvovaginal candidiasis (VVC) is a global health problem affecting ~75% of 27 
women at least once in their lifetime. Here we examined the epidemiology of 28 
VVC from a patient cohort to identify the causative organisms associated with 29 
VVC. Biofilm forming capacity and antifungal sensitivity profiles were also 30 
assessed. We report a shifting prevalence of Candida species with 31 
heterogeneous biofilm forming capacity, both of which are associated with 32 
altered antifungal drug sensitivity.  33 
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Fungal infections play a surprisingly substantial, yet unrecognised, health 34 
burden on the global population (1). Vulvovaginal candidiasis (VVC) is one 35 
example of these, where it is estimated to be the most common fungal infection 36 
in a number of countries worldwide (2-4). Approximately 138 million women 37 
worldwide complain of >4 episodes of VVC per year due to treatment failure, 38 
clinically defined as recurrent VVC (RVVC) (5-7). These unresolved infections 39 
not only have a high impact on the quality of life of these women, but can also 40 
lead to further health complications (8). Candida albicans is historically 41 
reported as the predominant organism isolated from VVC, accounting for over 42 
90% of infections (9, 10). However, evidence of a dynamic shift in yeast 43 
epidemiology has been demonstrated through an increasing prevalence of 44 
non-C. albicans species (NCAS), which accounts for 11-80% of infections, 45 
depending on geographical location (11). Nevertheless, C. albicans, a well-46 
characterised biofilm-forming organism, remains a prominent pathogen in this 47 
disease. Resistance to antifungal therapy as a result of biofilm formation is a 48 
likely contributor to failed treatment. While it is widely accepted that biofilms 49 
contribute to the pathogenesis of bacterial vaginosis (BV) (12, 13), their role in 50 
VVC remains contested despite the overwhelming evidence to suggest 51 
otherwise (14-16). 52 
An anonymised series of high vaginal swabs (HVS, [n=300]) obtained from 53 
women attending GP and referral clinics in the NHS Greater Glasgow & Clyde 54 
area, for at least the second time throughout April 2016 (17). These women 55 
were symptomatic at the time of sampling, with the causative organism 56 
identified using matrix-assisted laser desorption/ionisation-time of flight 57 
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(MALDI-TOF), with Escherichia coli used pre and post yeast sampling to 58 
ensure accuracy of testing. 59 
 60 
Seventy one percent (n=212) identified as C. albicans, followed by 15% (n=47) 61 
C. glabrata, 6% (n=17) C. dubliniensis, 3% (n=10) C. parapsilosis (Figure 1). 62 
The remaining 5% of isolates included C. tropicalis, C. lusitaniae and C. 63 
guillermondii. These data are line with recent epidemiological patterns showing 64 
a shift in NCAS within VVC (11). However, a caveat of our study is the 65 
limitation of a single geographical location, which may influence the species 66 
distribution. Future studies should include various institutes globally in order to 67 
fully assess the shift in VVC epidemiology. 68 
To determine the biofilm forming capability of these isolates, all VVC strains 69 
(n=300) were standardised to 1 × 106 cells/mL in RPMI-1640 and grown as 70 
biofilms in 96 well plates for 24 h. Biofilms were washed with PBS and biomass 71 
assessed using the crystal violet (cv) assay (18). Here we have shown that 72 
vaginal isolates were able to form differential biofilms, regardless of species 73 
(Figure 2). C. albicans displayed the greatest heterogeneity with regards to 74 
biofilm biomass, with isolates ranging from OD570nm 0.008 to 1.478, with a 75 
mean of 0.416. The second most prevalent species, C. glabrata, had 76 
significantly lower biomass than C. albicans (p<0.05) and C. dubliniensis 77 
(p<0.01), with a mean OD570nm 0.271. This apparent biofilm heterogeneity may 78 
contribute to the management of VVC infections, as these communities are 79 
known to be notoriously recalcitrant to antifungal therapy, and biofilm 80 
heterogeneity has been shown to correlate with in vitro antifungal therapy (18). 81 
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Planktonic and biofilm antifungal susceptibility testing was carried out as 82 
described previously to determine the minimum inhibitory concentrations 83 
(MICs) (19). Briefly, cells were standardised in RPMI-1640 before being treated 84 
with fluconazole (FLZ) (Sigma, Dorset, UK) for 24 h, at a range of 85 
concentrations (0.0625 to 32 mg/L). Planktonic MIC’s (pMIC) were determined 86 
as the lowest concentration able to completely inhibit growth visually. Sessile 87 
MIC’s (sMIC) were performed on 24 h preformed biofilms, with sMIC recorded 88 
at 50% inhibition using an XTT (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-89 
tetrazolium-5-caboxanilide) metabolic reduction assay (20). Here we have 90 
shown FLZ, the first line antifungal used to treat VVC, was ineffective against 91 
most isolates, with planktonic MIC’s ranging from <0.0625 to >32 mg/L (Table 92 
1). Specifically, the pMIC50 for FLZ was 4 mg/L, for C. albicans, C. glabrata and 93 
C. dubliniensis, though for biofilms this was >32 mg/L. When planktonic cells 94 
were stratified based on C. albicans and NCAS it was shown that 41% and 95 
26% of the isolates were insensitive to FLZ at >32 mg/L, respectively. Whereas 96 
for sessile cells, this rose to 51% and 56% of the isolates, respectively. 97 
Interestingly, similar susceptibility profiles were observed for C. albicans and C. 98 
glabrata, despite C. glabrata known to be a low biofilm former (21). This 99 
reduced sensitivity in C. glabrata can be associated with its intrinsic resistance 100 
to fluconazole, due to the overexpression of multidrug transporters (22). 101 
VVC is not a reportable disease, making epidemiological studies difficult. 102 
However, this study provides a snapshot of the species identified within a VVC 103 
population, demonstrating that NCAS are responsible for an increasing number 104 
of these infections. This corresponds with previous studies reporting an on-105 
going dynamic shift in yeast epidemiology (23, 24), potentially driven by 106 
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inappropriate use of over-the-counter azoles (10). Irrespective, C. albicans 107 
remained the most dominant species in this study, which questions why a high 108 
number of isolates displayed reduced susceptibility to FLZ. We demonstrated 109 
the ability of these clinical isolates to form heterogeneous biofilms, and the 110 
presence of these communities in VVC may explain why C. albicans infections 111 
remain unresponsive to FLZ therapy; an antifungal highly ineffective against C. 112 
albicans biofilms (25). We cannot discount the potential for heteroresistance 113 
phenotypes within these populations (26). The contribution of biofilms to VVC 114 
pathogenesis remains poorly understood, though many researchers are 115 
beginning to consider them important determinants of disease (14, 15), further 116 
emphasising the need for research in this field. Collectively, the data from this 117 
investigation highlights the necessity for careful consideration of the causative 118 
organism in VVC, the biofilm phenotype and its accentuated antifungal 119 
sensitivity profiles, all of which may improve antifungal treatment in this area.   120 
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Figure 1: Distribution of organism isolated from VVC patients. Three 203 
hundred VVC isolates were identified using MALDI-TOF, with yeast species 204 
proportionally represented. 205 
 206 
Figure 2: VVC isolates display varied biofilm formation. Three hundred 207 
VVC isolates were screened for biofilm formation using a biomass stain, as 208 
described in the methods. Each isolate was tested in quadruplicate, with the 209 
mean represented. Statistical analysis was carried out using a one-way 210 
ANOVA (* p<0.05, ** p<0.01).  211 
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Table 1: Susceptibility profile of Candida vaginal isolates to fluconazole  212 
 213 
Fluconazole Minimum Inhibitory Concentration (mg/L) 
 
 
n = 300 
C. albicans 
(n=212) 
C. glabrata  
(n=47) 
C. dubliniensis  
(n=17) 
C. parapsilosis  
(n=10) 
Others 
 (n=14) 
PMIC* SMIC** PMIC SMIC PMIC SMIC  PMIC SMIC  PMIC SMIC 
Range 0.0625 
– >32 
0.125 -
 >32 
<0.0625 
– >32 
0.5 -
 >32 
0.125 –
 >32 
0.125 -
 >32  
1 - >32 1 - >32  0.0625 
– >32 
1 - >32 
MIC50 4 >32 4 >32 4 >32 1 4 1 >32 
MIC90 >32 >32  >32 >32 >32 >32  16 >32 >32 >32 
 214 
*PMIC – Planktonic minimum inhibitory concentration, **SMIC – sessile minimum inhibitory concentration 215 
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